Search All Content Point of Care Guidelines Search
Cardiac Biomarker Good for Kidneys, Too
PHILADELPHIA — NT-proBNP, a biomarker predictive of adverse cardiac events, may also be predictive of unfavorable chronic kidney disease outcomes in those with type 2 diabetes, Japanese researchers found.
Glycemic Control Reduces CV Risk
PHILADELPHIA — Diabetes patients who responded to glucose-lowering treatment also improved their risk for adverse cardiovascular outcomes, a Swedish observational study found.
Artificial Pancreas Works Well in Kids
PHILADELPHIA — Closed-loop insulin delivery, also known as the "artificial pancreas," may help improve overnight glycemic control in the youngest patients, researchers said here.
Arthritis Drug's Beta-Cell Effects Last
PHILADELPHIA — The arthritis drug abatacept (Orencia) appears to have effects on beta-cell function in type 1 diabetes even after treatment is stopped, researchers said here.
Belly Fat Loss Best to Halt Diabetes
PHILADELPHIA — Although two bariatric surgery techniques resulted in similar weight loss, the one that shaved more belly fat led to a better rate of diabetes remission, a substudy of the STAMPEDE trial found.
Fish Oil Fails to Reduce CV Event Risk
PHILADELPHIA — Omega-3 fatty acids did not reduce the rate of cardiovascular events in high-risk patients with prediabetes or diabetes followed for half a dozen years, the randomized ORIGIN trial found.
Diabetics Shed Pounds with Insulin Analog
PHILADELPHIA — An investigational basal insulin analog may actually help type 1 and type 2 diabetic patients lose weight, researchers reported here.
No Cancer Risk with Lantus
PHILADELPHIA — Three observational studies showed no increased risk of cancer with use of insulin glargine (Lantus) compared with other insulins in the short term, researchers reported here.
Belly Fat Has No Effect on BP Control Goal
PHILADELPHIA — In patients with type 2 diabetes receiving intensive blood pressure treatment, the amount of visceral fat did not have an impact on cardiovascular events.
No CV or Cancer Risk with Insulin
PHILADELPHIA — The longest trial to study insulin has concluded it has a neutral effect on cardiovascular outcomes and cancer incidence, researchers said.
Added NSAID Boosts Glycemic Control
PHILADELPHIA — Salsalate, an anti-inflammatory agent similar to aspirin, may moderately boost glycemic control when added to current oral anti-diabetic regimens, researchers found.
Gastric Bypass Cuts Diabetes in Mild Obesity
PHILADELPHIA — Gastric bypass may be an effective treatment for type 2 diabetes in patients who are only mildly obese, researchers said here.
Fish Oil Takes Down Lipids in Diabetics
PHILADELPHIA — Diabetics with mixed dyslipidemia who were on statins improved their lipid profiles, without worsening glycemic control, with a novel omega-3 fatty acid drug, according to researchers here.
HbA1c May Predict Tx Failure in Diabetic Kids
PHILADELPHIA — Glycated hemoglobin levels and insulin secretion may forecast how children with type 2 diabetes will respond to therapy, researchers said here.
Uptick in Diabetes Cases Seen Among Youth
PHILADELPHIA — The prevalence of type 1 and type 2 diabetes rose in the early 21st century among adolescents in the U.S., researchers said here.
Byetta Wins Out as Add-On Therapy
PHILADELPHIA — The GLP-1 receptor agonist exenatide (Byetta) was superior to glimepiride (Amaryl) as an add-on therapy once patients with type 2 diabetes had failed on metformin, researchers found.
Systems Approach Aids Diabetes Care
PHILADELPHIA — Strategies to improve the quality of diabetes care work better when aimed at patients and the healthcare system rather than at individual doctors, results of a large meta-analysis suggested.
Insulin May Be Better Second Step
PHILADELPHIA — Jumping right to insulin glargine (Lantus) after patients with type 2 diabetes fail metformin may offer advantages in glucose control over add-on sitagliptin (Januvia), researchers found.
Move Off 'Prediabetes' Just Once Cuts Risk
PHILADELPHIA — Achieving normal glucose regulation just once predicted a lower risk of progression to diabetes for prediabetic patients, follow-up data from the Diabetes Prevention Program showed.
Cancer Risk of Insulin Key Focus at ADA
PHILADELPHIA — Clinicians are hoping to get some answers about whether insulin analogs raise the risk of cancer from analyses of two large registries that will be presented at this year's American Diabetes Association meeting.
American College of Cardiology Foundation